Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
This trial is conducted globally. The purpose of the trial is to evaluate that activated
recombinant human factor VII (eptacog alfa (activated)) is safe and effective in severely
injured trauma patients by assessing mortality and morbidity.
Please note that this trial and trial F7TRAUMA-1648 (NCT00323570) have been merged.